VaxGen’s rPA102 Recombinant Anthrax Vaccine
April 15, 2004 by admin · Leave a Comment
On April 15, 2004 VaxGen, Inc. announced that it had started the Phase II clinical testing of rPA102, its recombinant anthrax vaccine. VaxGen indicated that this 13-month trial is one of two studies under a $80.3 million agreement with the NIH’s National Institute of Allergy and Infectious diseases. The purpose of this study, involving 480 [...]
DAC GLP-1 for Type II Diabetes
April 12, 2004 by admin · 2 Comments
On April 12, 2004 ConjuChem Inc. announced interim Phase II results for DAC™: GLP-1. The company released results for patients who had received the first 28 days of therapy of the planned 3 month trial. Based on approximately 80 patients to date, ConjuChem reported a statistically significant reduction in Hgb A1C and glucose normalization or [...]